Dicerna Pharmaceuticals is part of the healthcare sector and is part of the biotechnology industry. The company CEO is Douglas M. Fambrough. Dicerna Pharmaceuticals Inc is a biopharmaceutical company. It develops ribonucleic acid interference-based pharmaceuticals for treating diseases involving liver, including rare, chronic liver, cardiovascular and viral infections.



Previous Intraday Performance:

The DRNA shares had a previous change of 0.36% which opened at 13.68 and closed at 13.84. It moved to an intraday high of 14.03 and a low of 13.66.

SeekingAlpha:  Ionis’s Spinraza Still Bests Novartis’s Zolgensma

Historical Performance:

Over the last five trading days, DRNA shares returned -4.09% and in the past 30 trading days it returned 17.89%. Over three months, it changed 26.51%. In one year it has changed 23.24% and within that year its 52-week high was 17.98 and its 52-week low was 9.31. DRNA stock is 48.66% above its 52 Week Low.

Our calculations result in a 200 day moving average of 13.20 and a 50 day moving average of 12.80. Right now, DRNA stock is trading 4.87% above its 200 day moving average and may be a good opportunity to buy.

SeekingAlpha:  Ionis’s Spinraza Still Bests Novartis’s Zolgensma

Liquidity:

The company has a market cap of $944.8m with 68.3m shares outstanding and a float of 68.0m shares. Trading volume was 195,806 shares and has experienced an average volume of 523,931 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.

Earnings:

The last annual reported EPS for Dicerna Pharmaceuticals was -1.61 which ended on 31st of December 2018. Based on 5 analyst estimates, the consensus EPS for the next quarter is -0.22.

Base on our calculations, the intrinsic value per share is 3.06, which means it might overvalued by -351.80%

The next earnings report will be: 04-30-2019

EPS growth is an important number as it indicates the future prospects of Dicerna Pharmaceuticals; it is usually expressed as a percentage and is then referred to as the EPS growth rate, which at this time is hard to estimate, but revenue growth has been 136.20% over the last twelve months.



Indicators Also to Watch:

Based on the latest filings, there is 0.50% of insider ownership and 104.30% of institutional ownership.

I calculated the beta to be 2.37

SeekingAlpha:  Celestica Inc. 2018 Q4 – Results – Earnings Call Slides

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is -58.89%, return on assets is -33.53%, price-to-sales is 203.28 and price-to-book is 4.69.

Company Score Card:

Results are out of six:
 2  : Growth Expectations Result
 6  : Financial Safety Result
 0  : Past Performance Result
 0  : Valuation Result
 0  : Dividend Safety Result
 2  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).

LEAVE A REPLY

Please enter your comment!
Please enter your name here